title: Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives.
abstract: Allosteric receptor modulation is an attractive concept in drug targeting because it offers important potential advantages over conventional orthosteric agonism or antagonism. Allosteric ligands modulate receptor function by binding to a site distinct from the recognition site for the endogenous agonist. They often have no effect on their own and therefore act only in conjunction with physiological receptor activation. This article reviews the current status of allosteric modulation at family C G-protein coupled receptors in the light of their specific structural features on the one hand and current concepts in receptor theory on the other hand. Family C G-protein-coupled receptors are characterized by a large extracellular domain containing the orthosteric agonist binding site known as the "venus flytrap module" because of its bilobal structure and the dynamics of its activation mechanism. Mutational analysis and chimeric constructs have revealed that allosteric modulators of the calcium-sensing, metabotropic glutamate and GABA(B) receptors bind to the seven transmembrane domain, through which they modify signal transduction after receptor activation. This is in contrast to taste-enhancing molecules, which bind to different parts of sweet and umami receptors. The complexity of interactions between orthosteric and allosteric ligands is revealed by a number of adequate biochemical and electrophysiological assay systems. Many allosteric family C GPCR modulators show in vivo efficacy in behavioral models for a variety of clinical indications. The positive allosteric calcium sensing receptor modulator cinacalcet is the first drug of this type to enter the market and therefore provides proof of principle in humans.
authors.affiliation: Department of Chemistry and Biochemistry, University of Berne, P/A Weissensteinweg 3, CH-3303 Jegenstorf, Berne, Switzerland. stephan.urwyler@ioc.unibe.ch
authors.forename: Stephan
authors.initials: S
authors.lastname: Urwyler
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D058786:GABA-B Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D058788:GABA-B Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D058990:Molecular Targeted Therapy; D044169:Receptors, Calcium-Sensing / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000378:metabolism; D013650:Taste Buds / Q000187:drug effects / Q000378:metabolism
chemical_list: D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D008024:Ligands; D044169:Receptors, Calcium-Sensing; D043562:Receptors, G-Protein-Coupled; D018080:Receptors, GABA-B